All News

HOPO Therapeutics jointly awarded $1.78M ARPA-E Grant

Phase 1 Clinical Trial of HOPO 14-1 Now Recruiting

CEO Julian Rees named 2023 Activate Fellow

Launch of Phase 1 Clinical Trial for HOPO 14-1

Poets & Quants names HOPO Therapeutics a 2022 Most Disruptive MBA Startup

HOPO Therapeutics named as an awardee in CLS Inspire QuickFire Challenge for BIPOC Communities

Berkeley Haas Features HOPO & VP Hannah Weber

HOPO Therapeutics completes California Life Sciences FAST Program

The team-focused advising program provided frequent mentoring from experts in a range of regulatory, business development and technical fields Learn about FAST